In Brief: Searle
Searle: Parexel named by company as preferred provider for pharmaceutical clinical development services. Pharmaceutical companies have been looking to consolidate their use of contract research organizations as one aspect of recent downsizing moves. The agreement with Boston-based Parexel will allow Searle to retain an internal research & development staff of "about half the size needed to satisfy all needs and contingencies internally," Searle said...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth